Andy

Washington, D.C., June 03, 2024 (GLOBE NEWSWIRE) — Children’s National Hospital is pleased to welcome Alda Mizaku in a newly established role of vice president and chief data and artificial intelligence officer (CDAIO). In this role, Mizaku will lead the execution of enterprise data, analytics and artificial intelligence (AI) strategy at Children’s National.

Mizaku has a track record of leading initiatives with measurable organizational value, from reducing unnecessary length of stay to enhancing operational efficiency and patient outcomes. Prior to joining Children’s National, Mizaku spent 11 years working for Mercy Health System in St. Louis, where she served in various roles, including executive director of Data Engineering and Analytics, and vice president of Analytics Product Management.

At BioHealth Innovation Inc. (BHI), we are happy to celebrate the achievements of our partner company, miRecule, which has recently been named a winner at the INVEST Pitch Perfect competition. miRecule’s innovative approach to RNA therapies represents a significant advance in the treatment of cancer and muscular dystrophy. By leveraging genomic data to design highly specific therapeutics, miRecule stands at the forefront of personalized medicine, underscoring our commitment to supporting ground-breaking healthcare solutions.

This recognition is not just a win for miRecule; it’s a testament to the power of strategic partnerships and the impact of innovative biotechnological advances in addressing complex health challenges. BHI is proud to be associated with pioneers like miRecule, as we continue to foster a thriving ecosystem that brings revolutionary treatments from the lab to the patients who need them most.

COLUMBIA, Md., (May 29, 2024) — TEDCO, Maryland’s economic engine for technology companies, unveiled the recently completed “Cybersecurity Workforce Analysis and Study” (“Study”). The Study was commissioned by TEDCO to better understand the current status of Maryland’s cybersecurity workforce pipeline. This knowledge will be used to guide the Cyber Maryland Program (“Program”) and its 18-member board of directors as they develop a statewide cybersecurity workforce development strategic plan.

“The Study confirms what businesses and government agencies in Maryland already know: demand for skilled cybersecurity professionals—who protect our communities from criminals threatening our way of life—is incredibly nuanced. Thankfully, there is support and momentum amongst key stakeholders to bridge our talent gap,” said Roger Austin, chair of the Cyber Maryland board of directors. “My fellow board members and I are committed to address this critical need by developing innovative solutions to overcome our cyber skills talent gaps and provide good, paying jobs for our state’s residents.”

COLUMBIA, Md. (May 30, 2024) – The Maryland Stem Cell Research Commission (“the Commission”) announces the release of Requests for Applications (RFAs) for the Maryland Stem Cell Research Fund’s (MSCRF) first funding cycle of fiscal year 2025 (FY25).

RFAs for this initial cycle are now available for five grant programs: Manufacturing Assistance, Clinical, Validation, Commercialization, and Launch. All applications are due by July 9, 2024.

Along with this announcement comes the news that the Commission is also extending grant funding to businesses outside of Maryland for the Commercialization grant program, provided the research activities are conducted within the State. The Clinical grant program is available to entities with at least one clinical site in Maryland.

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) — Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced the clearance of its second Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-531, a first-in-class oral treatment that selectively targets T-regulatory cells and spares other immune cells such as CD4 and CD8. The news comes just on the heels of the company’s first-in-class, dual-functioning antibody, GIM-122, progressing to clinical trial for human testing.

BALTIMORE, MD, US, May 29, 2024 /EINPresswire.com/ — Linshom Medical, a Maryland-based startup developing a wearable respiratory monitoring system, announced today that it has been awarded a $100,000 grant from the Maryland Industrial Partnerships (MIPS) program to support a clinical study of its respiratory monitoring device.

The study, “Advanced Prediction of Respiratory Depression Episodes with Linshom Continuous Predictive Respiratory Monitoring (CPRM),” will evaluate the Linshom Medical device’s ability for early detection of patient respiratory decline in the Post Anesthesia Care Unit. Dr. Samuel M. Galvagno, Executive Vice Chair of Anesthesiology and Interim Chair of the Department of Anesthesiology, will lead this effort for UMSOM as the principal investigator.

NEW YORK – AMPEL BioSolutions is recruiting individuals with systemic lupus erythematosus (SLE) into an observational study of its blood-based prognostic gene expression assay LuGene to demonstrate a correlation between test results and standard clinical evaluations.

In addition, the company has been conducting a study to see whether different lupus subtypes as defined by its test correlate with therapeutic response.

These studies follow another one published in October in the journal Genome Medicine that showed evidence for eight transcriptionally defined SLE endotypes, or subgroups, and demonstrated LuGENE’s ability to predict patients at risk for episodes of worsening symptoms called flares with high sensitivity and specificity.